NO20043279L - Kombinasjoner som innbefatter epotiloner og antimetabolitter - Google Patents

Kombinasjoner som innbefatter epotiloner og antimetabolitter

Info

Publication number
NO20043279L
NO20043279L NO20043279A NO20043279A NO20043279L NO 20043279 L NO20043279 L NO 20043279L NO 20043279 A NO20043279 A NO 20043279A NO 20043279 A NO20043279 A NO 20043279A NO 20043279 L NO20043279 L NO 20043279L
Authority
NO
Norway
Prior art keywords
antimetabolites
combinations
epothilones
include epothilones
Prior art date
Application number
NO20043279A
Other languages
English (en)
Norwegian (no)
Inventor
John David Rothermel
John Arthur Hohneker
Paul M J Mcsheehy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20043279L publication Critical patent/NO20043279L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20043279A 2002-01-14 2004-08-05 Kombinasjoner som innbefatter epotiloner og antimetabolitter NO20043279L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34862202P 2002-01-14 2002-01-14
US41617302P 2002-10-04 2002-10-04
PCT/EP2003/000232 WO2003057217A1 (en) 2002-01-14 2003-01-13 Combinations comprising epothilones and anti-metabolites

Publications (1)

Publication Number Publication Date
NO20043279L true NO20043279L (no) 2004-08-05

Family

ID=26995808

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043279A NO20043279L (no) 2002-01-14 2004-08-05 Kombinasjoner som innbefatter epotiloner og antimetabolitter

Country Status (16)

Country Link
US (3) US20060089327A1 (zh)
EP (2) EP2030618A3 (zh)
JP (1) JP2005513167A (zh)
KR (1) KR20040078123A (zh)
CN (1) CN1615136A (zh)
AU (1) AU2003235761A1 (zh)
BR (1) BR0306861A (zh)
CA (1) CA2471509A1 (zh)
IL (1) IL162595A0 (zh)
MX (1) MXPA04006822A (zh)
NO (1) NO20043279L (zh)
NZ (1) NZ533940A (zh)
PL (1) PL369670A1 (zh)
RU (1) RU2346686C2 (zh)
TW (1) TWI341728B (zh)
WO (1) WO2003057217A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CA2499682A1 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Epo d + 5-fu/gemcitabine
WO2005020989A1 (en) * 2003-09-02 2005-03-10 Novartis Ag Cancer treatment with epothilones
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
RU2447891C2 (ru) * 2006-04-05 2012-04-20 Новартис Аг Комбинации терапевтических средств, предназначенные для лечения рака
JP2009532497A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US2705727A (en) 1952-07-10 1955-04-05 Du Pont Synthesis of ureas
US2933498A (en) 1954-12-28 1960-04-19 Burroughs Wellcome Co 7-aminothiazolo-(5,4-d) pyrimidine
US3116282A (en) 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US4393064A (en) 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US4760135A (en) 1984-09-06 1988-07-26 University Of Kentucky Research Foundation Phloretin and phlorizin derivative containing compounds
IL77133A (en) * 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
ES2031462T3 (es) 1986-03-24 1992-12-16 Nippon Kayaku Kabushiki Kaisha Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
EP0443028B1 (en) * 1989-01-05 1993-09-29 Otsuka Pharmaceutical Co., Ltd. Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer
AU654555B2 (en) 1991-05-27 1994-11-10 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
EP1367057B1 (de) 1996-11-18 2008-09-17 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilone E und F
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2324378T3 (es) 1998-02-05 2009-08-05 Novartis Ag Composicion farmaceutica que contiene epotilona.
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP1058679B1 (en) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
ATE248175T1 (de) * 1998-12-22 2003-09-15 Novartis Pharma Gmbh Epothilonderivate und ihre verwendung als antitumormittel
AU771089B2 (en) * 1999-02-22 2004-03-11 Bristol-Myers Squibb Company C-21 modified epothilones
EP1181013B1 (en) * 1999-04-14 2006-10-11 Dana-Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome

Also Published As

Publication number Publication date
IL162595A0 (en) 2005-11-20
AU2003235761A1 (en) 2003-07-24
US20090298791A1 (en) 2009-12-03
EP2030618A3 (en) 2009-03-11
MXPA04006822A (es) 2004-12-08
TWI341728B (en) 2011-05-11
US20110082101A1 (en) 2011-04-07
CN1615136A (zh) 2005-05-11
WO2003057217A1 (en) 2003-07-17
EP1469847A1 (en) 2004-10-27
BR0306861A (pt) 2004-11-03
RU2346686C2 (ru) 2009-02-20
NZ533940A (en) 2007-06-29
JP2005513167A (ja) 2005-05-12
EP2030618A2 (en) 2009-03-04
KR20040078123A (ko) 2004-09-08
US20060089327A1 (en) 2006-04-27
RU2004124943A (ru) 2005-08-10
TW200306185A (en) 2003-11-16
PL369670A1 (en) 2005-05-02
CA2471509A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
DK3473251T3 (da) Nikotin-cellulose-kombination
DK1569712T3 (da) Forbindelsesindretning
ATE457980T1 (de) Aryloxime
ATE534648T1 (de) C-6-modifizierte indazolylpyrrolotriazine
ATE318817T1 (de) Aza-arylpiperazine
ATE427876T1 (de) Luftkissenboot
DE50212360D1 (de) Anfahrhilfesteuerungsvorrichtung
DE50212349D1 (de) Hirurgie
ATE349458T1 (de) Etonogestrelester
DE60331717D1 (de) Zündunterbrecherschaltkreis
ATA1572002A (de) Managementspleisskassette
NO20043279L (no) Kombinasjoner som innbefatter epotiloner og antimetabolitter
DE50301960D1 (de) Hydrolager
DE50311365D1 (de) Bohrvorrichtung
DE50301464D1 (de) Schraubensicherung
DE50302660D1 (de) Stopfmachine
DE50306167D1 (de) Polyisocyanatharze
DE50303404D1 (de) Rückflussverhinderer
ATE469773T1 (de) Zugöse
DE50303317D1 (de) Einschub-leistungsschalter
ATA19152002A (de) Hubkupplung
DE60311211D1 (de) Zapfhahn
DE10244834B8 (de) Suszeptometer
DE50303658D1 (de) Postgutmessvorrichtung
DE50300322D1 (de) Zylinderkopfdichtung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application